68Ga-XACP3 PET/CT for detecting prostate cancer lesions
PET Targeting Acid Phosphatase 3 (ACP3) in Prostate Cancer and Compared With 68Ga-PSMA
NA · The First Affiliated Hospital of Xiamen University · NCT07242014
This study will test whether 68Ga-XACP3 PET/CT can find tumor lesions in adults with prostate cancer or suspected recurrence compared with the standard 68Ga-PSMA PET/CT.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | Male |
| Sponsor | The First Affiliated Hospital of Xiamen University (other) |
| Locations | 1 site (Xiamen, Fujian) |
| Trial ID | NCT07242014 on ClinicalTrials.gov |
What this trial studies
Researchers will give participants contemporaneous 68Ga-XACP3 and standard 68Ga-PSMA PET/CT scans for initial staging, metastasis evaluation, or suspected recurrence. Tumor uptake will be measured quantitatively using SUVmax and lesions will be counted by visual interpretation on each scan. The diagnostic accuracy of 68Ga-XACP3 will be calculated and directly compared to the standard-of-care 68Ga-PSMA PET/CT. Results will show whether the new ACP3-targeting tracer identifies the same or additional lesions relative to PSMA imaging.
Who should consider this trial
Good fit: Adults (18+) with newly diagnosed prostate cancer, suspected recurrence, or previously treated metastases who are scheduled for 68Ga-PSMA PET/CT and can give informed consent are ideal candidates.
Not a fit: Patients who cannot undergo PET/CT, cannot provide informed consent, or are unable to travel to the study site are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, 68Ga-XACP3 PET/CT could improve lesion detection and help guide treatment decisions for patients with prostate cancer.
How similar studies have performed: PSMA-targeted PET tracers are well established and sensitive for prostate cancer, while ACP3-targeting agents like 68Ga-XACP3 are novel with limited prior human data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (aged 18 years or older); * Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of prostate cancer (supporting evidence may include MRI, CT, tumor markers, and pathology report); * Patients who had scheduled both standard-of-care imaging (68Ga-PSMA PET/CT) and 68Ga-XACP3 PET/CT scans; * Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: * The inability or unwillingness of the research participant or legal representative to provide written informed consent.
Where this trial is running
Xiamen, Fujian
- The First Affiliated Hospital of Xiamen University — Xiamen, Fujian, China (RECRUITING)
Study contacts
- Study coordinator: Liang Zhao
- Email: wzhaoliang01@163.com
- Phone: 86 18818350620
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Prostate Cancer, PET/CT, ACP3